Histone deacetylases (HDACs) mediate MECP2 gene repression, and have also been suggested as therapeutic targets for Rett syndrome (Shukla and Tekwani, 2020), which may act on BDNF trafficking (Xu et al., 2014). Here, MECP2 is linked to Rett syndrome.